Prognostic biomarkers and clinical parameters in adults with atrial septal defect-related pulmonary arterial hypertension treated with sildenafil and beraprost combination therapy

Anudya Kartika Ratri, I. Gde Rurus Suryawan, Meity Ardiana, Andrianto, Stavros G. Drakos

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Altered biological and environmental factors have been linked to the development of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH) pathogenesis. Objectives: We determined the association between prognostic biomarkers and clinical parameters of pulmonary arterial hypertension (PAH) in adult Atrial Septal Defect (ASD) patients with right heart failure who were treated with sildenafil and beraprost combination therapy. Methods: We conducted an observational study using a cross-sectional design and examined the correlation between prognostic biomarkers (superoxide dismutase (SOD) and Platelet-derived growth factor-BB (PDGF-BB)) and clinical parameters (6 minute walking distance (6MWD) and echocardiography parameters (tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP)) in 41 adult patients with ASD diagnosed as pre-capillary pulmonary hypertension (WHO group 1) who were treated at the congenital outpatient clinic at Dr. Soetomo General Hospital Surabaya, Indonesia from October 1st to November 30th 2022. A Pearson correlation test was used to determine the correlation between normal distribution variables. Statistical analyses were done using SPSS software. Results: The results indicated a moderately negative relationship between PDGF-BB and 6MWD (Pearson, r = −0.320, p = 0.041) and a medium significantly negative relationship between PDGF-BB and TAPSE/PASP (Pearson, r = −0.347, p = 0.026). Conclusions: Lower circulating PDGF-BB is associated with better functional capacity and echocardiographic parameters in adult ASD-PAH patients receiving sildenafil and beraprost combination therapy. PDGF-BB may strongly be used as a treatment progress monitoring and prognostic biomarker.

Original languageEnglish
Article number101720
JournalProgress in Pediatric Cardiology
Volume73
DOIs
Publication statusPublished - Jun 2024

Keywords

  • 6MWD
  • Adult Atrial Septal Defect
  • Clinical parameters
  • PDGF-BB
  • Prognostic biomarkers
  • Pulmonary arterial hypertension
  • SOD
  • Sildenafil and beraprost combination therapy
  • TAPSE/PASP

Fingerprint

Dive into the research topics of 'Prognostic biomarkers and clinical parameters in adults with atrial septal defect-related pulmonary arterial hypertension treated with sildenafil and beraprost combination therapy'. Together they form a unique fingerprint.

Cite this